Venmax Drugs And Pharmaceuticals Ltd (BSE: 531015) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹21 Cr, it ranks #4,408 by market cap among the 6,197 Indian listed companies on FinBizNet, and #58 of 63 in Pharmaceuticals. At ₹13.55 (as of 16 Nov 2026), the share price is 57.0% below its 52-week high of ₹31.49 and 8.3% above its 52-week low of ₹12.51. The share price is down 46.0% over one year and down 14.2% over three months.
| Current Price | ₹13.55 |
|---|---|
| Market Cap | ₹21 Cr |
| BSE Code | 531015 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 68.2 |
| Return on Assets | 0.82% |
| 52-Week Range | ₹12.51 – ₹31.49 |
| 1-Year Price Change | -46.0% |
| 3-Month Price Change | -14.2% |
| Beta (1Y) | 0.24 |
| Headquarters | Hyderabad, Telangana |
| Website | www.venmaxdrugs.com |
Delivery averaged 76.8% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Venmax Drugs and Pharmaceuticals Limited engages in the business of pharmaceutical products, drug intermediaries, and API’s. The company was formerly known as Yenkey Drugs & Pharmaceuticals Ltd and changed its name to Venmax Drugs and Pharmaceuticals Limited in April 2009. Venmax Drugs and Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.
1. Pharmaceutical-This segment engages in the manufacture and sale of bulk drugs intermediates primarily in India. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Venmax Drugs And Pharmaceuticals Ltd | ₹21 Cr | 68.2 | — | — | -46.0% |
Listed by market capitalisation. Ratios are shown for context only.
Venmax Drugs And Pharmaceuticals Ltd is trading at ₹13.55, with a market capitalisation of ₹21 Cr.
Venmax Drugs And Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Venmax Drugs And Pharmaceuticals Ltd has a P/E of 68.2.
Venmax Drugs And Pharmaceuticals Ltd is listed on the BSE under the scrip code 531015.
Venmax Drugs And Pharmaceuticals Ltd's share price is down 46.0% over one year and down 14.2% over three months. Its 52-week range is ₹12.51 to ₹31.49.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.